Paloma Partners’s Intellia Therapeutics NTLA Stock Holding History

Paloma Partners’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-11,414	Closed	-$167K	–	1811
2019 Q4	$167K	Buy	+11,414	New	+$159K	﹤0.01%	2000
2018 Q2	–	Sell	-17,048	Closed	-$360K	–	2027
2018 Q1	$360K	Buy	+17,048	New	+$419K	0.01%	1542

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Paloma Partners's NTLA Position: Q1 2020 in Review

Paloma Partners sold out of Intellia Therapeutics (NTLA) in Q1 2020, closing a stake of 11,414 shares — an estimated $167K sold.

Paloma Partners first reported a position in NTLA in Q1 2018 and held it in 2 quarters. The position peaked at $360K in Q1 2018. 140 funds tracked by Wall St. Rank hold NTLA as of Q1 2020.

Paloma Partners reported no remaining Intellia Therapeutics position as of Q1 2020 after selling out during the quarter.
Paloma Partners sold 11,414 Intellia Therapeutics shares in Q1 2020, an estimated $167K.
Paloma Partners first reported a position in Intellia Therapeutics in Q1 2018 and held it in 2 quarters.
Paloma Partners's Intellia Therapeutics position peaked at $360K in Q1 2018.
140 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.